NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have been assigned an average rating of “Moderate Buy” from the ten research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $42.00.

Several research firms have weighed in on NAMS. Citigroup began coverage on NewAmsterdam Pharma in a report on Tuesday, June 17th. They set a “buy” rating and a $42.00 price target for the company. Stifel Nicolaus began coverage on NewAmsterdam Pharma in a report on Tuesday, June 10th. They set a “buy” rating and a $44.00 price target for the company. Royal Bank Of Canada raised their price target on NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an “outperform” rating in a report on Thursday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Saturday, September 27th. Finally, Wells Fargo & Company began coverage on NewAmsterdam Pharma in a report on Monday, August 25th. They set an “overweight” rating and a $45.00 price target for the company.

NewAmsterdam Pharma Trading Down 0.1%

NASDAQ:NAMS opened at $30.67 on Friday. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $31.81. The stock has a 50-day moving average price of $25.25 and a 200 day moving average price of $21.30. The stock has a market capitalization of $3.45 billion, a P/E ratio of -18.93 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The firm had revenue of $19.15 million during the quarter, compared to analysts’ expectations of $1.44 million. On average, research analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Transactions at NewAmsterdam Pharma

In other news, insider Johannes Jacob Piete Kastelein sold 50,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $24.29, for a total value of $1,214,500.00. Following the completion of the transaction, the insider owned 119,302 shares in the company, valued at approximately $2,897,845.58. The trade was a 29.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James N. Topper bought 1,260 shares of the company’s stock in a transaction dated Monday, September 8th. The stock was bought at an average price of $24.99 per share, with a total value of $31,487.40. Following the acquisition, the director owned 3,027,864 shares in the company, valued at approximately $75,666,321.36. This trade represents a 0.04% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 2,391 shares of company stock worth $58,424 and have sold 324,954 shares worth $7,844,906. 20.84% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of NewAmsterdam Pharma by 19.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company’s stock worth $80,000 after purchasing an additional 596 shares during the period. Northern Trust Corp purchased a new position in shares of NewAmsterdam Pharma in the 4th quarter worth approximately $556,000. PTM Wealth Management LLC purchased a new position in shares of NewAmsterdam Pharma in the 2nd quarter worth approximately $256,000. Arizona State Retirement System purchased a new position in shares of NewAmsterdam Pharma in the 1st quarter worth approximately $215,000. Finally, California State Teachers Retirement System boosted its holdings in shares of NewAmsterdam Pharma by 23.5% in the 4th quarter. California State Teachers Retirement System now owns 19,404 shares of the company’s stock worth $499,000 after purchasing an additional 3,694 shares during the period. Hedge funds and other institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.